50 assets in Angiosarcoma

Therapeutic assets addressing Angiosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Angiosarcoma	Memorial Sloan Kettering Cancer Center	P2	B (60)
Abemaciclib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
arx788 Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Carboplatin Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Dan-222 Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Datopotamab Deruxtecan Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Dostarlimab Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Durvalumab Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Encequidar Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Fianlimab Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Gsk 5733584 Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Ipilimumab Angiosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Irinotecan Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Ivonescimab Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Ladiratuzumab Vedotin Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Lasofoxifene Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Letrozole Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Metformin Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
N-Desmethyl-4-Hydroxytamoxifen Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Neratinib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Niraparib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Nivolumab Angiosarcoma	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Olaparib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Pertuzumab Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Pexidartinib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Rilvegostomig Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Sarilumab Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Talazoparib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Deruxtecan Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Duocarmazine Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Emtansine Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trebananib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trilaciclib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Tucatinib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Veliparib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Vepdegestrant Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
vv1 Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Zanidatamab Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Ganetespib Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
mk-2206 Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
Nelitolimod Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (50)
Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Immunoglobulin G1, Anti-(Human Neuregulin Receptor Her3) (Human Monoclonal U3-1287 Heavy Chain), Disulfide With Human Monoclonal U3-1287 ?-Chain, Dimer Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CC (46)
agx101 Angiosarcoma	Angiex, Inc.	P1	CC (43)
Balstilimab Angiosarcoma	Agenus Inc.	P1	CC (43)
Botensilimab Angiosarcoma	Agenus Inc.	P1	CC (43)
mq719 Angiosarcoma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Amcenestrant Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	C (39)